Delandistrogene moxeparvovec, known by the brand name Elevidys, received FDA approval for the treatment of Duchenne muscular dystrophy in children on June 22, 2023.

Umoja Biopharma Receives FDA Approval for IND Application of UB-VV111, a CD19 Targeted CAR T for Blood Cancers.

Vyvgart Hytrulo received FDA approval on June 20, 2023. It is approved for the treatment of adults with generalized myasthenia gravis (gMG) who are anti-acetylcholine receptor (AChR) antibody positive.

The European Medicines Agency (EMA) has given its approval to Bio-Thera Solutions for BAT1706 (Avzivi®, bevacizumab), a biosimilar of Avastin®.

Suflave was approved by the FDA on June 15, 2023. It is a prescription laxative used to cleanse the bowel in preparation for colonoscopy in adults.

Connext has revealed the initial successful administration of CNT201, its therapeutic solution for Dupuytren’s contracture, in patients.

Aug 2nd latest updates in the global new drug development field, including progress in new drug research and development, transaction information, and partnership developments.

Vertex reveals FDA approval of New Drug Application for Suzetrigine for treating moderate-to-severe acute pain.

The US Food and Drug Administration (FDA) approved Posluma injection on May 25, 2023.

PepGen reports encouraging results from low-dose group in ongoing CONNECT1-EDO51 Phase 2 trial for treating Duchenne Muscular Dystrophy with PGN-EDO51.

durlobactam/sulbactam, marketed under the brand name Xacduro, is FDA approved. The approval was granted on May 23, 2023.

Formycon AG announced the first enrollment in the Phase III "Lotus" study comparing FYB206/pembrolizumab with leading cancer drug Keytruda for safety and efficacy.